The production and use of cells as therapeutic agents in neurodegenerative diseases

被引:74
作者
Isacson, O
机构
[1] Harvard Univ, Sch Med, McLean Hosp, Ctr Neuroregenerat Res,Neuroregenerat Labs, Belmont, MA 02478 USA
[2] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Harvard Ctr Neurodegenerat & Repair, Boston, MA USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1016/S1474-4422(03)00437-X
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Although progressive neurodegenerative diseases have very different and highly specific causes, the dysfunction or loss of a vulnerable group of neurons is common to all these disorders and may allow the development of similar therapeutic approaches to the treatment of diseases such as amyotrophic lateral sclerosis, Parkinson's disease, and Huntington's disease. When a disease is diagnosed, the first step is to instigate protective measures to prevent further degeneration. However, most patients are symptom-free until almost all of the vulnerable cells have become dysfunctional or have died. There are known molecular mechanisms and processes in stem cells and progenitor cells that may be of use in the future design and selection of cell-based replacement therapies for neurological diseases. This review provides examples of conceptual and clinical problems that have been encountered in the development of cell-based treatments, and specific criteria for the effective use of cells in the future treatment of neurodegenerative diseases.
引用
收藏
页码:417 / 424
页数:8
相关论文
共 82 条
[51]   Continuous dopamine-receptor stimulation in advanced Parkinson's disease [J].
Nutt, JG ;
Obeso, JA ;
Stocchi, F .
TRENDS IN NEUROSCIENCES, 2000, 23 (10) :S109-S115
[52]  
Olanow C, 2002, MOVEMENT DISORD, V17, pS15
[53]   Dopamine-mediated regulation of striatal neuronal and network interactions [J].
Onn, SP ;
West, AR ;
Grace, AA .
TRENDS IN NEUROSCIENCES, 2000, 23 (10) :S48-S56
[54]  
PAKZABAN P, 1993, EXP BRAIN RES, V97, P13
[55]  
PEARLMAN SH, 1991, EXP BRAIN RES, V84, P303
[56]   Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage [J].
PerezNavarro, E ;
Arenas, E ;
Reiriz, J ;
Calvo, N ;
Alberch, J .
NEUROSCIENCE, 1996, 75 (02) :345-352
[57]   Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient [J].
Piccini, P ;
Brooks, DJ ;
Björklund, A ;
Gunn, RN ;
Grasby, PM ;
Rimoldi, O ;
Brundin, P ;
Hagell, P ;
Rehncrona, S ;
Widner, H ;
Lindvall, O .
NATURE NEUROSCIENCE, 1999, 2 (12) :1137-1140
[58]  
Piccini P, 2000, ANN NEUROL, V48, P689, DOI 10.1002/1531-8249(200011)48:5<689::AID-ANA1>3.3.CO
[59]  
2-E
[60]   Opinion - Neural stem cell therapy for neurological diseases: dreams and reality [J].
Rossi, F ;
Cattaneo, E .
NATURE REVIEWS NEUROSCIENCE, 2002, 3 (05) :401-409